Medicare AdvantageCoverageMedium impact
Zevaskyn (prademagene zamikeracel) - Medicare Advantage (Revised)
Humana·Dermatology, Pediatrics, Genetics +2 more·Medicare Advantage
Effective date
Jun 1, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage now covers Zevaskyn (prademagene zamikeracel), a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds in patients ages 6-65 with confirmed COL7A1 mutations. This is a NEW coverage policy effective June 1, 2026, requiring medical director review and prior authorization through the Corporate Transplant Department. Billing teams must implement new coding for this advanced cell therapy treatment.
Action Required
By May 12, 2026 (review date): 1) Billing team must update system to recognize HCPCS code J3389 (effective 1/1/2026) and all ICD-10-PCS codes (XHR0XGA through XHR7XGA) for Zevaskyn claims. 2) Implement MANDATORY prior authorization workflow: all Zevaskyn requests must be submitted to Corporate Transplant Department (1-866-421-5663, fax 502-508-9300, or transplant@humana.com) with medical director review required. 3) Update pre-authorization checklist to verify: (a) RDEB diagnosis confirmed via genetic testing showing COL7A1 mutations in both copies, (b) patient age 6-65 years, (c) presence of RDEB-characteristic wounds (blistering, chronic wounds, erosions, scarring). 4) Train billing and prior auth staff on new gene therapy coding requirements and documentation needs. 5) Update claim submission templates to include diagnosis code documentation and genetic testing confirmation. Claims submitted without prior authorization approval will be denied; failure to verify eligibility criteria will result in medically unnecessary denials.